About Mark

Mark Rogel specializes in patent matters pertaining to biotechnology. His practice includes US and international patent preparation and prosecution, freedom to operate and patentability analyses, and intellectual property due diligence. Mark has experience in a wide range of technologies, such as cellular and molecular biology, immunology, polypeptide and polynucleotide therapeutics, including RNAi and antisense therapeutics, therapeutic antibodies, recombinant vaccines, gene therapy, stem cell therapeutics, diagnostics, drug delivery systems, biological assay development, and biology-based clean energy.

View full bio

Experience

NantKwest – $238 Million IPO

NantKwest – $238 Million IPO

July 27, 2015

Cooley advised the underwriters on NantKwest, Inc.'s $238.3 million initial public offering. NantKwest is a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. The company now trades on The NASDAQ Global Select Market under the symbol NK.

Read more

Related contacts

Charlie Kim
Partner, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Kevin King
Partner, Washington, DC
Mark Rogel
Associate, Seattle
Karen Tsai
Special Counsel, Washington, DC
Kristin VanderPas
Partner, San Francisco
Phil Mitchell
Partner, New York
Carlos Ramirez
Partner, San Diego

Related Practices & Industries

Compensation and Benefits
Capital Markets
Tax
Intellectual Property
Life Sciences and Healthcare Regulatory

Five Prime Therapeutics IPO

Five Prime Therapeutics IPO

September 23, 2013

San Francisco – Cooley advised the underwriters on Five Prime Therapeutics' initial public offering. Five Prime is a San Francisco-based clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancers and inflammatory diseases. Five Prime now trades on the Nasdaq Global Market under the symbol "FPRX."

Jefferies, BMO Capital Markets and Wells Fargo Securities are acting as joint-book-running managers, and Guggenheim Securities is acting as co-manager for the offering.

Related contacts

David Peinsipp
Partner, San Francisco
Charlie Kim
Partner, San Diego
Drew Williamson
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Natasha Leskovsek
Of Counsel, Washington, DC
Mark Rogel
Associate, Seattle

Admissions and credentials

Washington

US Patent and Trademark Office

Memberships and affiliations

Washington Biotechnology and Biomedical Association

Washington State Patent Law Association

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.